Based on the latest data from August 2025, Pfizer (PFE) is trading at $24.76, positioning the stock in the "Value" zone between the 6.2x PE multiple ($11.79) and 18.6x PE multiple ($35.19). This indicates that the stock is trading at approximately 13x earnings, suggesting reasonable valuation with potential investment value. The current price sits comfortably above the "Undervalued" threshold but well below the higher PE boundaries, indicating the market is pricing the stock at a moderate earnings multiple. Historically, Pfizer's valuation has experienced significant fluctuations across different PE zones. From 2020 to early 2022, the stock frequently traded in the "Watch" and "Overvalued" zones, with prices reaching as high as $46.78 in December 2021, placing it near the 30.9x PE boundary. The most dramatic shift occurred during 2023-2024, when the stock moved from trading above 30x PE multiples down to the "Undervalued" zone, with prices falling as low as $22.03 in April 2025. This represented a substantial valuation contraction from overvalued levels to undervalued territory. The recent recovery to the "Value" zone suggests the market has found a more balanced valuation level, with the PE river chart showing a relatively stable trend after the significant compression period, indicating potential stabilization in the company's earnings multiple.